Results 211 to 220 of about 580,459 (300)

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Salvage Autologous Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma: Long-Term Efficacy and Safety Outcomes from a Single-Center Real-World Cohort. [PDF]

J Clin Med
Korkmaz G, Ceran F, Dagdas S, Akgun S, Kızılkaya K, Ceylan A, Ozturk F, Aydın MS, Isleyen E, Erdogan Yon ME, Ozet G.   +10 more
europepmc   +1 more source

Outcomes of refractory and early‐relapsed large B‐cell lymphoma patients after first‐line treatment in the prospective Real‐world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre‐CAR T era

British Journal of Haematology, EarlyView.
Stéphanie Guidez, Aurélien Belot, Fanny Cherblanc, Bastien Lesné, Sylvain Carras, Catherine Thieblemont, Fontanet Bijou, Cédric Rossi, Luc Mathieu Fornecker, Jehan Dupuis, Krimo Bouabdallah, Ludovic Fouillet, Adrien Chauchet, Benoit Tessoulin, Loic Ysebaert, Alice Pauc, Pascale Cony‐Makhoul, Remy Gressin, Gaelle Laboure, Antoine Bonnet, Sandy Amorim, Christophe Fruchart, Roch Houot, Gian Matteo Pica, Carole Soussain, Sophie Dennetiere, Cécile Leyronnas, Pauline Lionne‐Huyghe, Hervé Ghesquières, Pierre Sesques   +29 more
wiley   +1 more source

Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH‐MM‐15 Study

Cancer Science, EarlyView.
t(11;14)‐positive MM is a clinically distinct subgroup characterized by intermediate prognostic risk, modest response depth, and treatment‐dependent outcomes. ABSTRACT t(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor.
Taku Tsukamoto, Yuji Shimura, Shinsuke Mizutani, Takahiro Fujino, Haruya Okamoto, Mitsuhiro Itagaki, Hiroshi Handa, Takayuki Shimizu, Morio Sawamura, Tadao Ishida, Satoru Kosugi, Shuichi Ota, Makoto Yoshimitsu, Yutaka Shimazu, Isamu Sugiura, Hirohiko Shibayama, Shin‐ichi Fuchida, Hiroyuki Takamatsu, Akiko M. Saito, Hitoshi Kiyoi, Koichi Akashi, Itaru Matsumura, Akifumi Takaori‐Kondo, Junya Kuroda, Shinsuke Iida   +24 more
wiley   +1 more source

Allogeneic skin transplantation induces transient fibrosis that undergoes spontaneous regression in newts. [PDF]

Inflamm Regen
Hosomi K, Nagata M, Okada M, Hirano K, Yamada E, Nakagawa T, Maruyama K, Banda CH, Shiraishi M, Danno K, Chiba C, Narushima M.   +11 more
europepmc   +1 more source

Evolution of CAR‐T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies

Cancer Science, EarlyView.
CAR‐T therapy is evolving across four interconnected dimensions: functional engineering, manufacturing innovation, alternative cell sources, and in vivo CAR programming. Together, these advances address limitations in therapeutic efficacy, safety, manufacturing complexity, scalability, and accessibility, providing complementary paths toward the next ...
Yukimi Sakoda
wiley   +1 more source

Liver Organoids: From Disease Modelling to Regenerative Medicine

Cell Proliferation, EarlyView.
Liver organoids provide a versatile platform for disease modelling and drug discovery, leveraging stem cells and engineering techniques. They bridge research and clinical applications, offering significant potential for advancing precision medicine and regenerative therapies for liver diseases.
Tiepeng Wang, Xiaotian Qu, Jinhong Si, Junkang Meng, Ting Zhang, Shuliang Niu   +5 more
wiley   +1 more source

The different face of skin‐rash induced by brentuximab vedotin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri, Tullio Brunetti, Serena Rupoli, Gianluca Cafasso, Corrado Zengarini, Staphano Cedirian, Federico Bardazzi, Cosimo Misciali, Michela Starace, Claudio Agostinelli, Gaia Goteri, Erika Morsia   +11 more
wiley   +1 more source

Pancreatic β‐cell mitogenic regeneration in type 1 diabetes: A preclinical review

Diabetic Medicine, EarlyView.
Abstract Type 1 diabetes (T1D) is caused by autoimmune destruction of insulin‐producing pancreatic β‐cells, resulting in hyperglycaemia. The first‐line treatment for symptomatic T1D is exogenous insulin replacement to maintain glycaemic control.
James Cantley, Lisa Logie, Parth Narendran, Colin Dayan   +3 more
wiley   +1 more source

Immune‐competent organ‐on‐chip methodologies to study type 1 diabetes

Diabetic Medicine, EarlyView.
Abstract Aims Type 1 diabetes (T1D) is a self‐driving autoimmune condition leading to the death of insulin‐producing β‐cells of the pancreas. β‐cell‐reactive immune cell extravasation into the intra‐islet space is fuelled by a cycle of inflammation including immune, vascular and endocrine dysfunction. Since clinical pancreatic biopsy is contraindicated,
Maja Witowska, Luigi Margiotta‐Casaluci, Periklis Pantazis, Margarita Dominguez‐Villar, Victoria Salem   +4 more
wiley   +1 more source